Sanofi-aventis builds a New Vaccine Manufacturing Facility in France
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), the world's leading vaccine manufacturer, officially launched the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France, in a ceremony attended by Gérard Collomb, Senator and Mayor of Lyon, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, Dr. Elias A. Zerhouni, Science and Technology Adviser for sanofi-aventis.
AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA
- Details
- Category: AstraZeneca
AstraZeneca has announced top line results from the phase III trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that BRILINTA (ticagrelor), the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus clopidogrel, in the prevention of cardiovascular (CV) events in patients with ACS.
Novo Nordisk reaches settlements regarding Oil-for-Food activities
- Details
- Category: Novo Nordisk
Novo Nordisk announced today that it has entered into a consent agreement with the US Securities and Exchange Commission (SEC) and a deferred prosecution agreement with the US Department of Justice (DOJ) resolving their investigations of the company's sales to Iraq during 2000 to 2003 under the UN's Oil-for-Food programme.
Nycomed files European marketing authorisation application for Daxas®
- Details
- Category: Nycomed
Nycomed has announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Daxas® as a once-daily oral treatment for patients with COPD associated with chronic bronchitis. The MAA submission is based on encouraging results from four Phase III trials of Daxas (roflumilast) in the treatment of symptomatic COPD.
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has entered into an agreement to divest full commercial rights to Wellbutrin XL® in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation (NYSE, TSX: BVF), for $510 million (£340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany is starting Phase III with an innovative patch for female contraception that combines low dosed ethinylestradiol and gestodene. Approximately 3300 women will be enrolled into two global studies to evaluate the contraceptive reliability of the patch starting in May 2009.
Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement
- Details
- Category: Pfizer
Pfizer, Inc (NYSE: PFE), the world's premier biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.
More Pharma News ...
- GlaxoSmithKline update: influenza A (H1N1)
- Outcome of new Mirapexin®/Sifrol® (pramipexole) study
- Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors
- Pfizer Reports First-Quarter 2009 Results
- Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion
- Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
- Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Base